RGEN

Repligen sells consumables and equipment into biopharma manufacturing — a structurally attractive, recurring-revenue bioprocessing market. FY2025 marks a clear recovery from the post-COVID destocking trough: revenue grew 16.4% to $738M and net income rebounded to $48.9M (+291.6%) after a -$25.5M loss in FY2024, with operating income up 257.1% to $55.2M. The balance sheet is excellent — liabilities/equity of just 0.40x, $566M cash and $542M long-term debt — and R&D is being funded for growth (+25.4% to $54.2M), signaling management's focus on the long-term franchise rather than near-term margins.

The problem is that the stock already prices in a complete and durable recovery. At $132.02 it trades at 153.5x EPS and 10.1x sales, while profitability remains depressed at the early stage of the rebound: operating margin of just 7.5%, net margin 6.6%, and return on equity of 2.3%. Even on the recovering numbers, the valuation requires margins to expand back toward historical levels (the company earned $186M in FY2022 on $802M revenue) and growth to compound for years. Notably, operating cash flow actually fell 33.1% to $117M, so the earnings recovery is not yet matched by cash generation.